Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 33

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 33
---
 to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating
restrictions that could adversely impact our ability to conduct our business. Any of these events could significantly harm our business,
financial condition and prospects.

We believe the environment
for financing of small and micro-cap biotech companies remains challenging. While this may present acquisition and/or merger opportunities
with other companies with limited or no access to financing, any attendant financing is likely to be dilutive. We and our advisors
continue to evaluate financing options, including those connected to acquisitions and/or mergers, potentially available to us, including
fundraising and the partnering of assets and technologies of the Company. There can be no assurance that any of the courses of action
to finance the Company, will be successful. This requirement for additional financing in the short term represents a material uncertainty
that may cast doubt upon our ability to continue as a going concern. Should it become evident in the future that there are no realistic
financing options available to us which are actionable before our cash resources run out, then we will no longer be a going concern. In
such circumstances, we would no longer be able to prepare financial statements under paragraph 25 of IAS 1. Instead, the financial statements
would be prepared on a liquidation basis and assets would be stated at net realizable value and all liabilities would be accelerated to
current liabilities.

We believe there are adequate
options and time available to secure additional financing for the Company and after considering the uncertainties, we considered it appropriate
to continue to adopt the going concern basis in preparing the financial information.

Our ability to continue as
a going concern is dependent upon our ability to obtain additional capital and/or dispose of assets, for which there can be no assurance
we will be able to do on a timely basis, on favorable terms or at all.

Our operations are in early-stage development with no sources of recurring revenue and there is no assurance that we will successfully develop and license our product candidates or ever become profitable.

We are at a relatively early
stage of our commercial development. To date, we have generated a minimal amount of revenue from our product candidates. Our ability to
generate revenue and become and remain profitable depends, in part, on our ability to successfully find a licensing partner for our product
candidates, or other product candidates we may in-license or acquire, and have such candidates successfully commercialized. Our current
strategy is, once proof-of-concept of our product candidates has been established,